Organization | Immune Tolerance Network

Immune Tolerance Network Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Seattle WA United States (2000)

Organization Overview

First Clinical Trial

2001

NCT00014911

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Immune Tolerance Network (ITN)

Active Ingredients

Drugs in Phase 3 Trials (5)

azathioprine (imuran) (2 trials)

cyclophosphamide (cytoxan) (8 trials)

methylprednisolone (medrol) (5 trials)

prednisone (meticorten) (9 trials)

rituximab (rituxan) (6 trials)

Drugs in Phase 2 Trials (59)

abatacept (orencia) (5 trials)

acetaminophen (tylenol) (3 trials)

aciclovir (zovirax) (1 trial)

alefacept (Amevive) (1 trial)

alemtuzumab (campath) (6 trials)

allogeneic pancreatic islet cells (1 trial)

alpha-1 antitrypsin (Prolastin) (2 trials)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (4 trials)

artreg-csb (1 trial)

atorvastatin (lipitor) (1 trial)

autologous hematopoietic cell (1 trial)

autologous regulatory t cells (1 trial)

bactrim (1 trial)

belatacept (nujolix) (2 trials)

belimumab (benlysta) (2 trials)

bnt162b2 (1 trial)

bone marrow cells (2 trials)

bone marrow derived mesenchymal stem cells (1 trial)

brentuximab vedotin (adcetris) (1 trial)

carmustine (bicnu) (1 trial)

cat epidermis allergen (4 trials)

cyclosporine (sandimmune) (2 trials)

cytarabine (cytosar-u) (1 trial)

daclizumab (Zenapax) (1 trial)

diphenhydramine (benadryl) (3 trials)

dupilumab (dupixent) (1 trial)

etoposide (vepesid) (1 trial)

everolimus (zortress) (2 trials)

fludarabine (fludara) (1 trial)

ganciclovir (cytovene) (1 trial)

house dust mite allergen (1 trial)

insulin human (humulin) (1 trial)

melphalan (alkeran) (1 trial)

mesna (mesnex) (3 trials)

mrna-1273 (1 trial)

mycophenolate (myfortic) (6 trials)

nystatin (mycostatin) (1 trial)

omalizumab (xolair) (1 trial)

peanut (2 trials)

pentamidine (pentam) (2 trials)

p. pratense pollen extract (1 trial)

sargramostim (leukine) (2 trials)

short ragweed pollen allergen (2 trials)

siplizumab (2 trials)

sirolimus (rapamune) (8 trials)

sodium chloride (1 trial)

sulfamethoxazole (gantanol) (1 trial)

tacrolimus (prograf) (8 trials)

teplizumab (3 trials)

tezepelumab (1 trial)

timothy grass pollen allergen extract (Grastek) (2 trials)

Tiplimotide (1 trial)

tocilizumab (actemra) (1 trial)

trimethoprim (1 trial)

ustekinumab (stelara) (1 trial)

valganciclovir (valcyte) (1 trial)

vib4920 (1 trial)

Drugs in Phase 1 Trials (8)

aldesleukin (proleukin) (1 trial)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

cryopreserved ex vivo expanded polyclonal cd4+cd127lo/-cd25+ t regulatory cells (1 trial)

fcgamma1-fel d1 fusion protein (1 trial)

histamine (1 trial)

ibc-vs01 (1 trial)

immucothel (1 trial)

montanide isa 720 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arthritis (Phase 2)

Arthritis, Psoriatic (Phase 2)

Asthma (Phase 2)

Autoimmune Diseases (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Eczema (Phase 2)

Egg Hypersensitivity (Phase 2)

Food Hypersensitivity (Phase 2)

Glomerulonephritis, Membranous (Phase 2)

Granulomatosis with Polyangiitis (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hypersensitivity (Phase 2)

Hypersensitivity, Immediate (Phase 1)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Liver Diseases (Phase 2)

Liver Failure (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lupus Nephritis (Phase 2)

Microscopic Polyangiitis (Phase 3)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Nephritis (Phase 2)

Peanut Hypersensitivity (Phase 2)

Psoriasis (Phase 2)

Renal Insufficiency (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Systemic Vasculitis (Phase 3)

Vasculitis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 51
# of Trial APIs: 72